1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin